天津医药

• 短篇论著 • 上一篇    下一篇

阿魏酸钠治疗糖尿病肾病的临床观察

董巧荣,边如玉,曲媛,冯云生   

  1. 承德医学院附属医院
  • 收稿日期:2010-11-30 修回日期:2011-04-26 出版日期:2011-10-15 发布日期:2011-10-15
  • 通讯作者: 董巧荣

Surveying The Clinical Curative Effect of Sodium Ferulate On Diabetic Nephropathy

  • Received:2010-11-30 Revised:2011-04-26 Published:2011-10-15 Online:2011-10-15

PDF (PC)

2218

摘要： 摘要 目的 探讨阿魏酸钠对糖尿病肾病（DN）的疗效。方法 糖尿病肾病82例随机分成常规治疗组和阿魏酸钠治疗组，测定尿白蛋白的排泄率（UAER），血尿素氮（BUN），血清肌酐（SCr），空腹血糖（FBG）平均动脉压（MAP）,比较两组结果。结果 治疗4周后，阿魏酸钠组UAER、SCr、BUN、MAP显著下降（P<0.05，P<0.01），而常规治疗组上述指标治疗前后差异无显著性。结论 阿魏酸钠能降低DN患者的UAER、BUR、SCr、MAP，其机制可能与其减少内皮素的生成或抗拮内皮素与其受体结合有关。

关键词: 阿魏酸钠, 糖尿病肾病, 内皮素

Abstract: [Abstract]Objective：Survey the clinical curative effect of Sodium Ferulate on Diabetic Nephropathy。Methord：Eighty-two Diabetic Nephropathy patients，divided into Conventional Therapy Group and Sodium Ferulate Therapy Group randomly，determine Urine Albumn Excretory Rate(UAER)、Blood Urea Nitrogen(BUN)、Serum Creatinine(SCr)、 Free Blood Glucose(FBG) and Mean Artery Pressure (MAP)of all patients，and take the data of pretherapy and post-treatment by comparison。Result：Maintenance single therapeutic regimen for four weeks，in Sodium Ferulate Therapy Group，UAER、SCr、BUN、MAP are significantly cut down（P<0.05，P<0.01），compared with the prethrepy data。However，there is no significant diference between the pretherapy data and post-treatment data。 Conclude：Sodium Ferulate therapy on Diabetic Nephropathy，the value of UAER、BUR、SCr and MAP of patients decrease。Conceivable mechanism is that Sodium Ferulate could inhibit the secretion of endothelin，or degrade the process of binding of endothelin and its receptor。

Key words: Sodium Ferulate, Diabetic Nephropathy, Endothelin